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mal chest shadow, AEP should be consid-
ered in the differential diagnosis, and BAL
and/or transbronchial lung biopsy should be
performed to obtain a definite diagnosis.
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Prospective Study of
Lambert-Eaton
Myasthenic Syndrome
in Small Cell Lung
Cancer
To the Editor:
Small cell lung cancer (SCLC) is a
highly immunogenic tumor of neuroendo-
crine origin. Autoantibodies to tumor-as-
sociated antigens have been detected in up
to 68% of patients with SCLC,1 some-
times present before the presence of
symptomatic disease. The presence of au-
toantibodies has also been linked to prog-
nosis in lung cancer, although it is not
clear whether the presence of a host’s
immune response to tumor antigens im-
proves overall survival. In patients with
autoimmune paraneoplastic neurologic
disorders (PNDs), the identification of dis-
tinct clinical syndromes such as Lambert-
Eaton myasthenic syndrome (LEMS),
usually evident before tumor detection,
has been linked in retrospective studies to
improved survival compared with patients
with SCLC without PNDs.2 However, it is
not clear whether it is the lead-time bias in
detecting lung tumors early or an effect on
the tumor from circulating antibodies
(such as voltage-gated calcium channel
antibodies [VGCC] in LEMS) that im-
proves long-term survival.
We read with interest the report by
Payne et al.,3 which detailed their pro-
spective study of patients with SCLC to
establish the incidence of PNDs such as
LEMS in this cohort. They found 2 of 63
patients with SCLC (3%) had LEMS,
which was discovered concomitantly at
the time of SCLC diagnosis. A further
three patients had detectable VGCC an-
tibodies but no associated LEMS or
other PNDs. It was reported that multi-
variate analysis (Cox regression) was
used to evaluate the survival: the pres-
ence of VGCC was not associated with
improved survival, although their two
LEMS cases survived for 23.5 and 15.5
months. We suspect that they are correct
in their assumption that the study was
underpowered to detect an effect on sur-
vival from the presence of VGCC anti-
bodies, although they do not specify
what size of hazard ratio their study
was underpowered. Their data records
showed very low case recruitment rates
(an average of only six new SCLC cases
recruited each year for 10 years) and in-
cluded a larger proportion of males (73%)
than would be expected in a contemporary
SCLC cohort. In addition, a large number
of their study patients (86%) had extensive
disease. Because gender and disease stage
are well-established prognostic factors,
any bias of the study population toward
over-representation of a particular sub-
group may have affected their survival
statistics, and in particular the apparent
effect of VGCC antibodies if such prog-
nostic factors were not taken into account
in this analysis. There also seems to be an
error in reporting because the hazard ratio
is given as 0.999 yet has a rather implau-
sible p value of 0.08.
It is not clear from their report
whether Payne et al. have underestimated
the true incidence of LEMS in their cohort
of patients with SCLC. LEMS is almost
always identified before tumor discovery,
and such patients may not have ultimately
enrolled in their study after subsequent
SCLC diagnosis. With such low rates of
recruitment of patients with SCLC, there
may have been a number of patients in
their 10-year study period who developed
PNDs with SCLC but were not enrolled.
One of us (P.M.) has recently pub-
lished the first 100 cases in an ongoing,
prospective study of patients with SCLC
designed to determine whether the pres-
ence of onconeural antibodies, with or
without PNDs (including LEMS), is as-
sociated with a favorable prognosis.4
That study found a slightly higher inci-
dence of LEMS (4%) and a similar num-
ber of additional SCLC patients with
VGCC antibodies but no neurologic
symptoms (6%) even after follow-up.
When taking into account the additional
prognostic factors such as age, gender,
and disease extent, there was a slightly
better (not statistically significant) over-
all survival in VGCC antibody positive
patients. We suspect that the true value
of this ongoing prospective study will be
to differentiate whether the previously
reported improvement in survival of pa-
tients with LEMS and SCLC from ret-
rospective studies2 is due to the clini-
cian’s lead-time bias rather than an
effect of the VGCC antibodies them-
selves. As of February 2010, we have
enrolled 240 SCLC patients over a
4-year period, of whom 9 have LEMS
and VGCC antibodies and 11 have
VGCC antibodies but no associated
LEMS. Median survival time is 13.25
months among LEMS patients and
11.25 months for all patients with
VGCC antibodies. In 177 of our SCLC
study patients who had no PND or de-
tectable onconeural antibodies, the me-
dian survival is only 8.5 months. If it is
demonstrated that survival is improved
not only in LEMS patients with SCLC
but also in patients with VGCC antibod-
ies but no signs of LEMS, this may
indicate that it is the immunoreactivity
to tumor antigens such as VGCCs that is
contributing to better survival, perhaps
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as a result of regulating tumor cell dif-
ferentiation. It is possible that regula-
tion of calcium cellular influx may
modulate mitogenic signal transduction
pathways in SCLC tumors, potentially
inhibiting tumor cell proliferation.5
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Differences of Gene
Expression in Non-
small Cell Lung Cancer
Are Histology, Tumor
Site, and Methodology
Relevant?
To the Editor:
A number of studies have been
carried out to identify predictive bi-
omarkers of chemotherapy activity in
non-small cell lung cancer (NSCLC).
Unfortunately, the results obtained are
contradictory, and tailored treatment of
patients on the basis of gene expression
profiles is still far from being standard-
ized. A possible explanation could re-
side in differences of gene or protein
expression depending on tumor histol-
ogy or site of biopsy. Because only few
studies have tried to address this critical
point, we appreciated the article by
Kang et al.1 By means of immunohisto-
chemistry (IHC), they observed that the
expression of ERCC1 and XRCC1 was
similar in adenocarcinoma and squa-
mous cell carcinoma.
Accordingly, in our study,2 look-
ing at the expression level of genes
involved in gemcitabine and cisplatin
activity, with quantitative real time
(RT)-polymerase chain reaction (PCR)
analysis, we found that ERCC1 ex-
pression is not influenced by NSCLC
histology, suggesting that adenocarci-
noma and squamous cell carcinoma
have a similar genetic susceptibility to
platinum compounds. Indeed, a recent
clinical study3 showed that the out-
come after cisplatin-gemcitabine treat-
ment is similar in patients affected by
adenocarcinoma or squamous cell his-
tology tumors. Kang et al. also re-
ported that ERCC1 and XRCC1 were
overexpressed in neoplastic lymph
nodes compared with primary tumors.
On the contrary, we did not observe
any significant difference in expres-
sion with respect to the origin of the
specimens. The possible reasons for
data discrepancy could be due to not
only the different ethnicity of the pa-
tients (Asian versus Caucasian) but
also the different methods and targets.
Although the study included three
different proteins investigated in a rela-
tively small sample size, the authors did
not perform correction for multiple vari-
ables in their statistical method. Another
important point is the different technique;
in the work by Kang et al., protein expres-
sion was evaluated by IHC in paraffin-
embedded specimens, whereas we mea-
sured mRNA expression by quantitative
RT-PCR in laser-microdissected frozen
tumors. IHC is a sensitive and versatile
method, but it is largely empirical; the
outcome depends on the antibody used
and on the expertise of the pathologists. In
the specific case, there is not yet a consen-
sus about the antibody 8F1, which was
used by Kang et al.1 to detect the ERCC1
protein.4
Quantitative RT-PCR method is
a sensitive and specific technique, with
appropriate controls that can be used
for intralaboratory or interlaboratory
validation. We are aware that mRNA
can differ from protein expression, and
we believe that optimization of both
these methodologies and standardiza-
tion of technical procedures are neces-
sary before larger retrospective and
prospective studies can address the
same pharmacogenetic question. Other
critical points of the study regard the
heterogeneity of treatments and the
different stage and lymph node infil-
tration. All these factors could be con-
founding elements in the analysis of
correlation with outcome.
In conclusion, we agree with
Kang et al.1 that retrospective obser-
vational studies on histology and tu-
mor site can provide strong rationale
for future trials, but we believe that
optimization or standardization of
technical procedures and the use of
larger and uniformly treated popula-
tions are crucial before prospective
studies can identify the best markers
for tailored treatment of NSCLC pa-
tients.
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